TRANSFORMING CLINICAL AND TRANSLATIONAL RESEARCH AND EDUCATION AT ROCKEFELLER

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 洛克菲勒大学医院自1963年以来一直是GCRC的获奖者，自1910年以来一直是洛克菲勒临床和转化科学的“家”。它一直是许多具有里程碑意义的科学和临床贡献的网站，它的许多学员已经成为学术领袖。与 根据临床和转化科学奖（CTSA），一个核心的教师提供的新资源。 杰出的研究人员，其研究跨越基础翻译光谱，包括广泛的科学和医学学科，将整合和扩大他们的科学和教育 洛克菲勒大学临床和转化科学中心的一个新项目。新中心将通过鼓励新的研究，并通过加强和集中所需的支持结构，以科学的严谨性和绝对的承诺进行研究，从而改变临床和转化研究。 保护人类受试者和参与者安全。转型的关键要素将是：1）反映NIH合作协议（U 54）“援助”机制的新治理结构，2）创建新的K-12临床研究学者计划，提供硕士和博士学位，以补充 目前的临床学者，计划，3）基础设施的增强，以促进良好的临床实践（GCP）的原则下，包括生物医学信息学，生物统计学的临床方案的开发和实施。生物营养学、研究护理、研究药房、参与者招募和社区参与，以及来自临床研究（研究主题）的监管支持和监督 倡导者）支持办公室，4）开发与树突状细胞治疗相关的创新和新颖的核心方法;丙型肝炎和恶性肿瘤;遗传学/基因组学;评估免疫反应;和代谢表型。该中心将延续洛克菲勒的传统， 科学发现，人类病理生理学和新的诊断，预防和治疗策略之间的接口。它将在互利的情况下与工业界合作，以实现这些目标。该中心还将成为国家CTSA联盟的积极成员，为联盟提供新颖的想法 和工具进行和评估临床和转化研究。它还将积极采用联合会确定的最佳做法，并遵守联合会制定的标准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Rockefeller University Hospital, a GCRC awardee since 1963, has been the continuous "home" for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of. distinguished investigators, whose research spans the basic-translational spectrum and encompasses a broad range of scientific and medical disciplines, will integrate and expand their scientific and educational programs in a new Rockefeller University Center for Clinical and Translational Science. The new Center will transform clinical and translational research by encouraging new studies, and by enhancing and centralizing the support structures required to conduct studies with scientific rigor and an absolute commitment to protection of human subjects and participant safety. The key elements in the transformation will be: 1) A new governance structure reflecting the NIH cooperative agreement (U54) "assistance" mechanism, 2) Creation of a new K-12 Clinical Research Scholars Program offering Masters and PhD level degrees to complement the current Clinical Scholars,Program, 3) Infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of Good Clinical Practice (GCP), including biomedical informatics, biostatistics. bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office, 4) Development of innovative and novel core methodologies related to dendritic cell therapy; hepatitis C, and malignancies; genetics/genomics; assessing the immune response; and metabolic phenotyping. The Center will continue Rockefeller's tradition of focusing on the interface between scientific discovery, human pathophysiology, and novel diagnostic, preventive and therapeutic strategies. It will partner with industry, when mutually beneficial, to achieve these goals. The Center will also be an active member of the National CTSA Consortium, offering the Consortium novel ideas and tools for conducting and evaluating clinical and translational research. It will also eagerly adopt the best practices identified by the Consortium and adhere to the standards set by the Consortium.